StemCell Therapy

blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy
http://www.cordbloodrecommendation.com Umbilical cord blood is stored immediately after delivery, when the cord is cut. Diseases that are genetically based would most likely be an allogenic transplant. Human umbilical cord blood cells are very rich in stem cells and progenitor cells which make them the perfect place to take cells from and then store them in a cord blood bank or a stem cells bank. Scientists have found that umbilical blood can actually help to treat many types of medical issues. To make a long story short, the Adult Stem Cells did the trick. This would be a significant event, which would save thousands of lives of those waiting for an organ. Why would someone opt for cord blood preservation? Well, research is continually being conducted and cells extracted from this blood has already been used to treat and cure injuries and diseases. Cord Blood Banking facilities are places where you can bank your child #39;s cord blood and use it later on in life to cure life-threatening diseases. The National Cord Blood Program staff at the New York Blood Center performs cord blood collection from the expelled placenta. Because of this amazing capacity of blood cells, they have been, still are and will continue to be used more and more to save lives and cure a number of diseases. ""Umbilical cord blood contains blood-forming cells that can be used to treat life-threatening diseases and conditions. Stem cells, researchers discovered, could cure many diseases such as leukemia and ...From:hotelesenMelgarViews:0 0ratingsTime:01:18More inScience Technology

Originally posted here:
blood bank | The Development of Umbilical Cord Blood Stem Cell Therapy - Video

Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are cells which have the potential to develop into virtually any cells of the body. The characteristics of stem cells render them great possibility in treating illness as well as health rejuvenation. Stem cells can repair and renew damaged cells as well as replace the dead ones so that a damaged organ or tissue can be healed to its healthy state. Visit Stem Cell Malaysia at http:/stemcellmalaysia.com/ for more information on stem cells and stem cell therapy.From:stemcells2012Views:1 1ratingsTime:06:33More inHowto Style

The rest is here:
Stem Cells | Stem Cell Malaysia - Video

Washington, November 8 (ANI): Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function.

Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN.

"Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts," she stated.

Fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute added, "With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function."

"For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery," he noted.

Skarlatos said that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

The findings will be presented at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association. (ANI)

Visit link:
Bone marrow stem cell therapy does not improve short-term recovery after heart attack

Stem Cell Research and TNG
How close is Science to providing visors for the blind? Or what about curing blindness? Have you watched the episode "The Masterpiece Society" from season 5 of TNG? Cause I have a couple of philosophical things to say about that! An article about STEM CELL therapy in regards to vision impairment: abcnews.go.com Interview with TrekMate: http://www.trekmate.org.uk ***I feel like the Star Trek community is a lot bigger then what YouTube has to offer, so I #39;ve started uploading my own videos. A lot of you will find this painfully dorky -and it is- which is why constructive criticism is welcomed. For anyone who does like my posts, thank you! It would be nice to gather a little Trekkie community :)***From:ThatTrekkieGirlViews:6 1ratingsTime:06:51More inPeople Blogs

Visit link:
Stem Cell Research and TNG - Video

NEW YORK (AP) Shares of biotechnology company Pluristem Therapeutics Inc. bounced back Friday after the company responded to a report that a patient treated with its PLX stem cell therapy had died.

THE SPARK: Bloomberg BusinessWeek reported Thursday that Pluristem did not disclose the death of a young patient who had been treated with its placental cell therapy before a $32 million public stock sale in September. Shares of Pluristem fell 23 percent Thursday.

The Israeli company said Thursday evening that parts of the article were inaccurate or misleading. It said the patient, a Romanian girl whose name has not been disclosed, was "in imminent danger of death" at the time she was treated with the stem cells. She was not part of an organized clinical trial and was treated on a compassionate basis because no therapy options remained.

Pluristem said the patient lived for six months after her treatment. She returned to Romania four months before she died and the company was not monitoring her health. Pluristem said it was not aware of her death at the time it sold the additional stock. Bloomberg said the patient died Sept. 12, the day the stock sale was announced. The sale closed a week later.

"The formal report relating to the death clearly stated that there was no connection between the PLX cell treatment and the death of the patient," Pluristem said in a press release.

THE BIG PICTURE: Pluristem said that three patients have been treated with PLX on a compassionate basis including the Romanian girl and two have died. The company said it believes the patients lived longer than expected following treatment, which demonstrates that PLX therapy can be effective. The company is studying the stem cells as a treatment for peripheral artery disease, nerve pain, and other conditions.

THE STOCK: Shares of Pluristem rose 39 cents, or 13.7 percent, to $3.24 on Friday. The stock reached an annual high of $5 per share in August, and including Friday's gains, the shares are down 29 percent since the company announced the stock offering.

View original post here:
Pluristem shares bounce back after Thursday plunge

NEW YORK, NY--(Marketwire - Nov 8, 2012) - Stem cell stocks have been gaining popularity among investors in 2012 as new and promising research continues to propel the industry forward. A study performed earlier this year at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. ( NASDAQ : ASTM ) and Neostem Inc. ( NYSE : NBS ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/ASTM

http://www.FiveStarEquities.com/NBS

A more recent study, also conducted at Johns Hopkins University, has showed that stem cells donated by strangers were as safe and as effective as the patient's own cells in repairing heart tissue. This is a key advancement for the treatment of heart attack with stem cells, as this possibly means stem cells could be stored for use just as blood is now.

"You could have the cells ready to go in the blood bank so when the patient comes in for a therapy -- there's no delay," said Dr. Joshua Hare of the University of Miami. "It's also cheaper to make the donor cells," as marrow from a single donor could provide enough cells for the treatment of up to 10 people.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is a leader in the development of patient-specific multicellular therapies for the treatment of severe, chronic cardiovascular diseases. Stem cell therapy is the infusion, injection or transplantation of whole cells into a patient for the treatment of a disease or condition.

NeoStem is a provider of adult stem cell collection, processing and storage services in the United States, enabling healthy individuals to donate and store their stem cells for personal therapeutic use. In addition, the company collects and stores cord blood cells of newborns which help to ensure a supply of autologous stem cells for the child should they be needed for future medical treatment.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

See the original post:
Promising Stem Cell Research Driving Industry's Growth in 2012

PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:08:01More inPeople Blogs

Read more from the original source:
PURTIER Live Stem Cell Therapy - 4th Edition (Chinese Version).mp4 - Video

PRP Vs Stem Cell Therapy
PRP Therapy Vs Stem Cell TherapyFrom:MiamiFootSurgeryViews:4 0ratingsTime:01:23More inHowto Style

Link:
PRP Vs Stem Cell Therapy - Video

PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4
PURTIER Live Stem Cell Therapy - 4th Edition (English Version) Please contact Pearly @ +65 9338 9541 for more detailsFrom:PurtierPearlyViews:1 0ratingsTime:09:00More inPeople Blogs

Original post:
PURTIER Live Stem Cell Therapy - 4th Edition (English Version).mp4 - Video

RIO DE JANEIRO--(BUSINESS WIRE)--

CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses.

Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz.

ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1.

Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after the procedure. Objective evaluation of stress myocardium perfusion (scintigraphic analysis), after 1 year of follow-up, gave indications of complete myocardial reperfusion in 75% of the patients, says Dr. Nelson Hossne, Medical Director of CellPraxis. Our conclusion was ReACT's specific cell formulation, MonoCell, had a direct correlation to myocardial neoangiogeneses.

About CryopraxisTM (www.cryopraxis.com.br) and CellPraxis (www.cellpraxis.com)

Located at Bio-Rio Biotech Cluster (Rio de Janeiro, Brazil), CryopraxisTM is the pioneer and the largest bank of umbilical cord blood in Brazil and has been in operation since 2001, with approximately 25,000 customers. CellPraxis is a bioengineering company that invests in research projects involving stem cell therapy. Some of these projects are conducted in partnership with institutions like the Federal University of Rio de Janeiro, Federal University of So Paulo, the University of South Florida and Saneron CCEL Therapeutics, Inc. (a USA based biotechnology company dedicated to stem cell research).

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

See the original post:
Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina

Washington, November 7 (ANI): Stem cell therapy improves heart function in patients who had previous heart attacks, according to researchers from the University of Louisville and Brigham and Women's Hospital.

In a Late-Breaking Clinical Trial session at the American Heart Association Scientific Sessions 2012 meeting, Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Women's Hospital, Boston, presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks.

They report that after two years, all patients receiving the stem cell therapy show improvement in heart function, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF), a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat.

No adverse effects resulting from the therapy were seen. Moreover, MRIs performed on nine patients in the trial showed evidence of myocardial regeneration - new heart tissue replacing former dead tissue killed by heart attack.

"The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient," said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL.

"The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study," he stated.

The trial - called SCIPIO for Stem Cell Infusion in Patients with Ischemic CardiOmyopathy - was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower; the normal LVEF is 50 percent or higher.

The investigators harvested the CSCs, referred to as "c-kit positive" cells because they express the c-kit protein on their surface, from 33 patients during coronary artery bypass surgery. The stem cells were purified and processed in Anversa's lab in Boston so that they could multiply. Once an adequate number of stem cells was produced - about one million for each patient - Bolli's team in Louisville reintroduced them into the region of the patient's heart that had been scarred by the heart attack.

The researchers reported that in the 20 patients receiving CSCs, LVEF increased from 29 percent to 36 percent at four months following infusion. None of the 13 control patients in the trial received CSCs and this group showed, on average, no improvement.

The beneficial effect of the CSCs persisted and became progressively greater at the one- and two-year mark following infusion. At the one-year mark following infusion, LVEF increased by 8.1 percent, and at the two-year mark, by 12.9 percent.

Originally posted here:
Stem cell therapy improves heart function 2 years after heart attack

MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country.

Stem cell treatment involves the use of adult stem cells to treat a range of diseases.

The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens.

The regulation of laboratories and practitioners involves five key points.

First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses.

Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence.

Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy.

"Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go.

The DOH said consultations with stakeholders are still ongoing, but it expects a set of guidelines to be released by next month.

Continue reading here:
Stem cell therapy to be regulated in PH

Washington, November 6 (ANI)

Administering to patients stem cells derived from their own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial.

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous, related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function.

Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN.

"Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts," she stated.

Fellow CCTRN member Jay Travese, M.D., of the Minneapolis Heart Institute added, "With this baseline now set, we can start to adjust some of the components of the protocol to grow and administer stem cell to find cases where the procedure may improve function."

"For example, this therapy may work better in different population groups, or we might need to use new cell types or new methods of delivery," he noted.

Skarlatos said that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

The findings will be presented at the American Heart Association (AHA) 2012 Scientific Sessions in Los Angeles and will appear concurrently in the Journal of the American Medical Association.

View original post here:
Stem cell therapy may not improve recovery after heart attack

UPDATE on Stem Cell Therapy

7 November 2012

The Department of Health (DOH) saw the necessity to cover regulations for Stem Cell therapy. Stem Cell therapy belongs to the category of Advanced Cell therapy which includes biologics and blood. Many countries around the world apply a risk-based approach to assess the quality, efficacy and safety of advanced cell therapy. In many countries, Stem Cell is considered an investigational intervention.

Stem Cell research employs both autologous (from same person) or allogenic (from another organism like animal or another human cell or tissue sample) method. Because there are many steps in the preparation of this lab and invasive procedure, there is therefore need to have a regulatory framework to protect Filipino citizens.

Important questions were asked: is there proof of concept in animal trials where stem cell can then be applied in humans? Is there a way to ensure quality and purity of the raw materials? How safe is the procedure? How many did not benefit from the procedure? If this were investigational procedure, how will human subjects be protected?

Sec. Enrique Ona convened a consultative working task force to provide recommendations on how to proceed in the early part of the year in response to queries and mushrooming of centers here and overseas. This led to the creation of a regulatory task force to oversee the appropriate steps that will ensure quality, efficacy and safety documentation of this intervention.

See the original post:
UPDATE on Stem Cell Therapy 7 November 2012

Public release date: 6-Nov-2012 [ | E-mail | Share ]

Contact: Steve Goodyear sgoodyear@mhif.org 952-807-8365 Minneapolis Heart Institute Foundation

MINNEAPOLIS, MN November 6, 2012 Administering autologous stem cells obtained from bone marrow either 3 or 7 days following a heart attack did not improve heart function six months later, reports a new clinical trial supported by the National Institutes of Health. The results of this trial, called TIME (Transplantation In Myocardial Infarction Evaluation), were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation Tuesday, Nov. 6, at the 2012 Scientific Sessions of the American Heart Association in Los Angeles.

The results of this trial mirror a previous, related study (LateTIME) which found that autologous bone marrow stem cell therapy given 2-3 weeks after a heart attack did not improve cardiac recovery. Both TIME and LateTIME were carried out by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

"The data presented by TIME do much to advance stem cell therapy research," said Jay Traverse, MD of the Minneapolis Heart Institute Foundation and Principal Investigator of this study. "While this study did not provide a demonstrated cardiac benefit after six months, we still learned a great deal. Together, TIME and Late TIME have shown that stem cell therapy is safe, and they have set a baseline in terms of quantity of stem cells, type of stem cells, and severity of heart attack."

TIME enrolled 120 volunteers (avg. age 57) between July 2008 and February 2011; the participants all had moderate to severe impairment in their left ventricle and had undergone coronary stent placement as treatment for the heart attack. The participants were randomly assigned to one of four groups: day 3 stem cell, day 3 placebo (inactive cells), day 7 stem cell, or day 7 placebo. The CCTRN researchers developed a method of processing and purifying the stem cells from the bone marrow of each volunteer to ensure everyone received a uniform dose (150 million stem cells).

Heart improvement was assessed six months after stem cell therapy by measuring the percentage of blood that gets pumped out of the left ventricle during each contraction (left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six month follow-up in either the Day 3 or Day 7 stem cell groups compared with placebo or with each other; every group showed about a 3 percent improvement in LVEF. However, the researchers found that younger patients randomized to Day 7 had greater improvement in their LVEF compared to their placebo counterparts

"The lack of six-month improvement seen for TIME and, prior to that, LateTIME, does not mean stem cell therapy is not a viable post-heart attack strategy," said Traverse. "Because we have this data we can start to address some parameters; for example this therapy may work better in younger people, or maybe we need to use cells from healthy volunteers (allogeneic) since their cells may provide greater therapeutic benefit. There will also be upcoming studies using novel cell types which we look forward to using in future clinical trials."

###

For further information see:

More:
Stem cell therapy using patient's own cells after heart attack does not enhance cardiac recovery

April Flowers for redOrbit.com Your Universe Online

Conflicting studies were highlighted at this years American Heart Association Scientific Sessions meeting concerning stem cell therapy for heart attack patients.

The first study, from the University of Louisville and Brigham and Womens Hospital, reported holy grail results for a Phase I clinical trial: marked sustained improvement in all patients with zero adverse effects.

Roberto Bolli, M.D., of the University of Louisville and Piero Anversa, M.D., of Brigham and Womens Hospital presented data from their groundbreaking research in the use of autologous adult stem cells with patients who had previous heart attacks in a Late-Breaking Clinical Trial session.

The researchers report that all patients receiving the stem cell therapy showed improved heart function after two years, with an overall 12.9 absolute unit increase in left ventricular ejection fraction (LVEF). LVEF is a standard measure of heart function that shows the amount of blood ejected from the left ventricle during a heartbeat. They saw no adverse effects from the therapy. In fact, nine patients showed evidence of myocardial regeneration new tissue replacing formerly dead tissue killed by heart attack in MRI scans.

The trial shows the feasibility of isolating and expanding autologous stem cells from virtually every patient, said Bolli, who is the Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the Institute for Molecular Cardiology in the Department of Medicine at UofL. The results suggest that this therapy has a potent, beneficial effect on cardiac function that warrants further study.

In all patients, cells with high regenerative reserve were obtained and employed therapeutically, said Anversa, professor of Anesthesia and Medicine at Brigham and Womens Hospital and Harvard Medical School. Our efforts to carefully characterize the phenotype and growth properties of the cardiac stem cells may have contributed to these initial positive results.

The Stem Cell Infusion in Patients with Ischemic CardiOmyopathy, or SCIPIO, trial was a randomized open-label trial of cardiac stem cells (CSCs) in patients who were diagnosed with heart failure following a myocardial infarction and had a LVEF of 40 percent or lower. A normal LVEF reading is 50 percent or higher.

The CSCs, referred to as c-kit positive cells because they express the c-kit protein on their surface, were harvested from 33 patients during coronary artery bypass surgery. The stem cells were then purified and processed so that they could multiply, and once an adequate number was produced about one million for each patient they were reintroduced into the region of the patients heart that suffered scarring during the heart attack.

At four months after infusion, the researchers report that LVEF increased from 29 percent to 36 percent for 200 patients. On average, the 13 control patients who did not receive a CSC infusion showed any improvement.

More:
Studies On Stem Cell Therapy After Heart Attack Show Mixed Results

cord blood center | Cord Blood Transplantation - A Life Savior Technique
http://www.cordbloodrecommendation.com Storing your babies blood is painless, and causes no harm or pain to the child or mother. Anything that can help cure illnesses and several genetic diseases is worth at least researching and contemplating because you really do never know when you may need it. This type of stem cells is found in baby cord blood and adult bone marrow. Umbilical blood banking provides the ideal stem cell match should a patient require stem cell therapy in their lifetime. Hence opt for cord blood storage banks that can show proof of successful transplants from the cord blood units they have stored in order to avoid rude shocks. If you are an expecting mother, you can look for a bank or designated donation hospital in your community. In cases of leukemia, stem cells can be used to generate healthy blood and fight off the cancer cells in the body. Furthermore, collecting umbilical cord blood has no controversy since the process does not cause the destruction on the embryos and fetus. ""Leukemia is a type of cancer that begins from those tissues in the body that form blood. Ultra-modern cord blood banking technologies induce multiplication of cord blood stem cells by ex vivo expansion. Last but not the least, if you do not want to store the blood for your personal usage in any of these banks you can also donate it to the Medical Institutes for research purposes. Stem cells, researchers discovered, could cure many diseases such as leukemia and help others such as ...From:Implantes DentalesViews:1 0ratingsTime:01:31More inTravel Events

Read more from the original source:
cord blood center | Cord Blood Transplantation - A Life Savior Technique - Video

FAQ-11 of 19: For Stem Cell Therapy, Why Thailand #39;s Licensed Stem Cell Treatments?
youtu.be You may wonder why coming to Thailand is a better investment of time, energy and resources, so here are some answers. For more personalized information as to how your condition might respond to stem cell therapy, go to the Apply Now page and send in copies of your medical records with an Application for Consideration. StemCell-Asia.infoFrom:Karridine1Views:1 0ratingsTime:01:16More inPeople Blogs

Go here to read the rest:
FAQ-11 of 19: For Stem Cell Therapy, Why Thailand's Licensed Stem Cell Treatments? - Video

Arthritis
Call: 305-695-7777 For More Information Arthritis has been something historically very hard to cure, but we maybe one step closer to a cure by using stem cell therapies instead of steroids and other types of medications. At Miami Beach Foot and Ankle Surgery we have been utilizing PRP (platelet rich plasma) therapy as well as amniotic stem cell therapy, which is important in the world of arthritis.From:MiamiFootSurgeryViews:11 0ratingsTime:01:12More inHowto Style

Read the original post:
Arthritis - Video

Muscular Dystrophy Before and After Stem Cell Therapy
He took stem cell therapy at NeuroGen. Previously when he was climbing stairs, he was widening steps and climbing stairs. And he was taking more time, now he is taking less time. Climb stairs straight. Previously during sit to stand, he was taking support of hands and was coming up, but now he is not taking support. Previously when he was sitting on floor, he was facing in coming up and facing problem in walking few steps. But after stem cell therapy he can walk normally now. Now changes are seen. Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:0 0ratingsTime:00:37More inScience Technology

Continue reading here:
Muscular Dystrophy Before and After Stem Cell Therapy - Video